Literature DB >> 31805278

ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway.

Rensong Ye1, Zhenwei Liu2.   

Abstract

This study aimed to investigate the protective effect of angiotensin converting enzyme 2 (ACE2) on lipopolysaccharide (LPS)-induced acute lung injury (ALI). After generating ALI mouse models by injecting LPS, the levels of ACE2, inflammatory factors, and downstream proteins of the LPS-TLR4 pathway were analyzed. LPS-challenged BEAS-2B cells were established in vitro. Next, a eukaryotic expression vector, pm-ACE2, was constructed and validated. Challenged cells were transfected with pm-ACE2 containing enhanced green fluorescent protein, or they were treated with D-Ala-Ang-(1-7), angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) and the LPS-TLR4 pathway inhibitor dimethyl fumarate (DMF) for analysis of how the above factors contribute to ACE2 regulation. Expression of renin, Ang II, ACE and angiotensin II type 1 receptor (AT1R) was subsequently assessed. In the ALI model, mice exhibited decreased expression of ACE2, lung pathological injury, inflammatory injury, and abnormal activation of the LPS-TLR4 pathway. LPS-challenged BEAS-2B cells demonstrated upregulated expression of renin, Ang II, ACE and AT1R. After injection of ACE2, lung function and lung pathological injury were significantly improved, and that effect was accompanied by attenuated inflammation, and inactivation of the LPS-TLR4 pathway. Cell studies showed similar results. The above observations were further enhanced when there was a combined treatment with DMF and pm-ACE2. D-Ala-Ang-(1-7) treatment attenuated the protective effect of ACE2, while ACEI and ARB treatment alleviated LPS-induced pneumonic injury. In conclusion, ACE2 was expressed at low levels in response to LPS-induced ALI. Overexpression of ACE2 regulates the ACE2/Ang-(1-7)/Mas and ACE/Ang II/AT1 axes to maintain dynamic balance of the renin-angiotensin system, and attenuate inflammatory response.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACE/Ang II/AT1 axis; ACE2/Ang-(1–7)/mas axis; Acute lung injury; Angiotensin converting enzyme 2; LPS-TLR4 pathway; Lipopolysaccharide; Renin-angiotensin systems

Year:  2019        PMID: 31805278     DOI: 10.1016/j.yexmp.2019.104350

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  63 in total

Review 1.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Authors:  Andrew M South; Tammy M Brady; Joseph T Flynn
Journal:  Hypertension       Date:  2020-05-05       Impact factor: 10.190

2.  Protective Effects of Carbon Dots Derived from Armeniacae Semen Amarum Carbonisata Against Acute Lung Injury Induced by Lipopolysaccharides in Rats.

Authors:  Yusheng Zhao; Yue Zhang; Hui Kong; Guoliang Cheng; Huihua Qu; Yan Zhao
Journal:  Int J Nanomedicine       Date:  2022-01-04

3.  Silence of MLK3 alleviates lipopolysaccharide-induced lung epithelial cell injury via inhibiting p53-mediated ferroptosis.

Authors:  Xiangjun Chen; Gangqiang Qi; Fang Fang; Yi Miao; Li Wang
Journal:  J Mol Histol       Date:  2022-03-05       Impact factor: 2.611

Review 4.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

5.  Anti-inflammatory effects of N-Acetylcysteine and Elaeagnus angustifolia extract on acute lung injury induced by λ-carrageenan in rat.

Authors:  Morteza Mamashli; Saeed Nasseri; Yaser Mohammadi; Sahar Ayati; Asghar Zarban
Journal:  Inflammopharmacology       Date:  2022-06-20       Impact factor: 5.093

Review 6.  ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.

Authors:  Ravindra K Sharma; Bruce R Stevens; Alexander G Obukhov; Maria B Grant; Gavin Y Oudit; Qiuhong Li; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Hypertension       Date:  2020-08-12       Impact factor: 10.190

7.  Whole transcriptome analysis of the differential RNA profiles and associated competing endogenous RNA networks in LPS-induced acute lung injury (ALI).

Authors:  Xiangnan Teng; Jing Liao; Lili Zhao; Wei Dong; Haiyi Xue; Lang Bai; Shanling Xu
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

Review 8.  New perspectives on natural flavonoids on COVID-19-induced lung injuries.

Authors:  Fernanda Paula R Santana; Fernanda Thevenard; Kaio S Gomes; Laura Taguchi; Niels Olsen S Câmara; Roberta S Stilhano; Rodrigo P Ureshino; Carla Maximo Prado; João Henrique Ghilardi Lago
Journal:  Phytother Res       Date:  2021-04-29       Impact factor: 6.388

9.  Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation.

Authors:  Wei Wang; Sha-Sha Li; Xin-Feng Xu; Chan Yang; Xiao-Ge Niu; Shu-Xian Yin; Xiao-Yan Pan; Wei Xu; Guo-Dong Hu; Chan Wang; Shu-Wen Liu
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

10.  SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage.

Authors:  Yongjun Sui; Jianping Li; David J Venzon; Jay A Berzofsky
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.